GOLDEN, Colo. — September 14, 2021 – PharmaJet®, the maker of innovative, needle-free injection technology, today announced that its partner, Scancell, has selected its devices to administer its two SARS-CoV-2 DNA vaccine candidates, SCOV1 and SCOV2. The vaccines will be exclusively administered using the PharmaJet Tropis® and PharmaJet Stratis® Needle-free Injection Systems.
Scancell’s COVIDITY-001 study, including the use of the two PharmaJet systems, has been approved by the South African regulatory authority. This program is a collaboration between Scancell and scientists in the newly established Centre for Research on Global Virus Infections and the new Biodiscovery Institute at the University of Nottingham, and Nottingham Trent University. Preclinical studies have confirmed that PharmaJet delivery of the COVIDITY vaccines induces potent immune responses against both S and N antigens.
Professor Lindy Durrant, Chief Executive Officer, Scancell commented, “Our preclinical studies have shown that delivery of SCOV1 and SCOV2 with the PharmaJet Needle-free injection Systems generates excellent T cell and antibody responses. In addition, they are easy-to-use and ideal for people who are needle-phobic, an important cause of vaccine hesitancy. We look forward to progressing our COVIDITY-001 study in South Africa and updating the market in due course.”
Chris Cappello, President and CEO, PharmaJet, said, “We are pleased to be collaborating with Scancell as they start their clinical trials with this innovative vaccine approach. Our Needle-free Systems have shown improved immune response for multiple DNA and RNA vaccines and are used globally to deliver vaccines for diseases such as influenza, Covid-19 , measles and polio.”
For more information about PharmaJet visit pharmajet.com.
Refer to Instructions for Use to ensure safe injections and to review risks.
PharmaJet’s mission is to improve people’s lives through needle-free technology. PharmaJet Needle-free Systems provide increased vaccine effectiveness, a preferred patient and caregiver experience, and a proven path to commercialization. They are also safe, fast, and easy-to-use. The Stratis® System has U.S. FDA 510(k) marketing clearance, CE Mark, and WHO PQS certification to deliver medications and vaccines either intramuscularly or subcutaneously. The Tropis® System has CE Mark and WHO PQS certification for intradermal injections. For more information visit pharmajet.com.
Scancell Holdings plc is a biopharmaceutical company focused on the cancer therapeutics market and is developing a pipeline of immunotherapies for the treatment of cancer based on its patented ImmunoBody®, Moditope® and AvidiMab™ platforms. In response to the COVID-19 pandemic, Scancell has turned its clinical expertise in cancer to produce a simple, safe, cost-effective, and scalable vaccine to induce both durable T cell responses and virus neutralizing antibodies against SARS-Cov-2, the virus that causes COVID-19. For more information go to scancell.co.uk.